Limits...
Development of Budesonide Loaded Biopolymer Based Dry Powder Inhaler: Optimization, In Vitro Deposition, and Cytotoxicity Study.

Mali AJ, Pawar AP, Purohit RN - J Pharm (Cairo) (2014)

Bottom Line: At same time, serious systemic side effects of drugs have become a cause for concern.The subject of present study, lactose-free budesonide loaded biopolymer based DPI, further corroborates the great potential of antiasthmatic drugs.This technology is expected to revolutionize the approaches towards enhanced therapeutic delivery of prospective drugs.

View Article: PubMed Central - PubMed

Affiliation: Department of Pharmaceutics, Poona College of Pharmacy, Bharati Vidyapeeth University, Erandwane, Pune, Maharashtra 411038, India.

ABSTRACT
The progress in the development of DPI technology has boosted the use of sensitive drug molecules for lung diseases. However, delivery of these molecules from conventional DPI to the active site still poses a challenge with respect to deposition efficiency in the lung. At same time, serious systemic side effects of drugs have become a cause for concern. The developed budesonide loaded biopolymer based controlled release DPI had shown maximum in vitro lung deposition with least toxicity. The subject of present study, lactose-free budesonide loaded biopolymer based DPI, further corroborates the great potential of antiasthmatic drugs. This technology is expected to revolutionize the approaches towards enhanced therapeutic delivery of prospective drugs.

No MeSH data available.


Related in: MedlinePlus

Percentage cell viability against alveolar epithelial cancer cell line A549 of formulated budesonide and blank DPI and its excipients. Data are presented as mean ± SD, n = 3.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4590799&req=5

fig7: Percentage cell viability against alveolar epithelial cancer cell line A549 of formulated budesonide and blank DPI and its excipients. Data are presented as mean ± SD, n = 3.

Mentions: As the microparticles are intended to provide control release, it is necessary to test for local toxicity of the formulation and its excipients [45]. Therefore, in vitro cell viability for optimized budesonide loaded biopolymer based DPI was evaluated against alveolar epithelial cancer cell line A549 using MTT assay and compared with blank formulation, free budesonide, and formulation excipients (Figure 7). At 500 μM concentration, all the tested formulations showed more than 80% cell viability, whereas the blank formulation and chitosan showed 64% and 4.9% cell viability, respectively. However, the concentrations of all the excipients used were less than 500 μM. Even, at 1000 μM concentration, the formulated budesonide DPI showed 71.7% cell viability. The improved cell viability in the formulated DPI due to negative charge of engineered particles and controlled release of the drug from rigid polymeric chains of gelled biodegradable sodium alginate microparticles leads to lower cellular internalization [46]. The results indicated that the formulated biopolymer based DPI was safe up to 1000 μM.


Development of Budesonide Loaded Biopolymer Based Dry Powder Inhaler: Optimization, In Vitro Deposition, and Cytotoxicity Study.

Mali AJ, Pawar AP, Purohit RN - J Pharm (Cairo) (2014)

Percentage cell viability against alveolar epithelial cancer cell line A549 of formulated budesonide and blank DPI and its excipients. Data are presented as mean ± SD, n = 3.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4590799&req=5

fig7: Percentage cell viability against alveolar epithelial cancer cell line A549 of formulated budesonide and blank DPI and its excipients. Data are presented as mean ± SD, n = 3.
Mentions: As the microparticles are intended to provide control release, it is necessary to test for local toxicity of the formulation and its excipients [45]. Therefore, in vitro cell viability for optimized budesonide loaded biopolymer based DPI was evaluated against alveolar epithelial cancer cell line A549 using MTT assay and compared with blank formulation, free budesonide, and formulation excipients (Figure 7). At 500 μM concentration, all the tested formulations showed more than 80% cell viability, whereas the blank formulation and chitosan showed 64% and 4.9% cell viability, respectively. However, the concentrations of all the excipients used were less than 500 μM. Even, at 1000 μM concentration, the formulated budesonide DPI showed 71.7% cell viability. The improved cell viability in the formulated DPI due to negative charge of engineered particles and controlled release of the drug from rigid polymeric chains of gelled biodegradable sodium alginate microparticles leads to lower cellular internalization [46]. The results indicated that the formulated biopolymer based DPI was safe up to 1000 μM.

Bottom Line: At same time, serious systemic side effects of drugs have become a cause for concern.The subject of present study, lactose-free budesonide loaded biopolymer based DPI, further corroborates the great potential of antiasthmatic drugs.This technology is expected to revolutionize the approaches towards enhanced therapeutic delivery of prospective drugs.

View Article: PubMed Central - PubMed

Affiliation: Department of Pharmaceutics, Poona College of Pharmacy, Bharati Vidyapeeth University, Erandwane, Pune, Maharashtra 411038, India.

ABSTRACT
The progress in the development of DPI technology has boosted the use of sensitive drug molecules for lung diseases. However, delivery of these molecules from conventional DPI to the active site still poses a challenge with respect to deposition efficiency in the lung. At same time, serious systemic side effects of drugs have become a cause for concern. The developed budesonide loaded biopolymer based controlled release DPI had shown maximum in vitro lung deposition with least toxicity. The subject of present study, lactose-free budesonide loaded biopolymer based DPI, further corroborates the great potential of antiasthmatic drugs. This technology is expected to revolutionize the approaches towards enhanced therapeutic delivery of prospective drugs.

No MeSH data available.


Related in: MedlinePlus